TherapeuticsMD Inc (NASDAQ:TXMD) shares gapped up before the market opened on Wednesday . The stock had previously closed at $6.57, but opened at $6.36. TherapeuticsMD shares last traded at $6.31, with a volume of 848,336 shares traded.

A number of research analysts have recently commented on TXMD shares. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, May 12th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a research note on Wednesday, May 24th. Jefferies Group LLC set a $15.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, June 14th. Oppenheimer Holdings, Inc. upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Tuesday, July 11th. Finally, CIBC upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. TherapeuticsMD has a consensus rating of “Buy” and an average price target of $16.14.

The company’s 50-day moving average price is $5.83 and its 200 day moving average price is $5.56. The stock’s market capitalization is $1.41 billion.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The business had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) EPS. Equities research analysts predict that TherapeuticsMD Inc will post ($0.44) EPS for the current fiscal year.

In related news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was purchased at an average cost of $5.99 per share, with a total value of $29,950.00. Following the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at $21,294.45. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Carl Domino Inc acquired a new position in TherapeuticsMD in the 2nd quarter valued at $235,000. Raymond James Financial Services Advisors Inc. raised its holdings in TherapeuticsMD by 56.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after acquiring an additional 10,330 shares in the last quarter. Stifel Financial Corp increased its stake in shares of TherapeuticsMD by 125.4% in the 1st quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after purchasing an additional 238,885 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of TherapeuticsMD by 94.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock valued at $298,000 after purchasing an additional 20,148 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of TherapeuticsMD by 2.5% in the 1st quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after purchasing an additional 329,245 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD Inc (TXMD) Shares Gap Up to $6.36” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/08/therapeuticsmd-inc-txmd-shares-gap-up-to-6-36-2.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.